Imfinzi

Imfinzi is a cancer drug developed by AstraZeneca, specifically a PD-L1 inhibitor used to treat various types of tumors by helping the immune system attack cancer cells.

Why it’s in the news: It is in the news because a competitor, China's Akeso, reported that its own cancer drug outperformed Imfinzi in a late-stage clinical trial.

Latest on Imfinzi

• China’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial

Connections

3 entities linked to Imfinzi across the news graph.